Study to investigate how AI could aid early detection of pancreatic cancer
5th May 2021
Researchers from Barts Cancer Institute at Queen Mary University of London and Edge Hill University are set to investigate how artificial intelligence could be used to improve early diagnosis of pancreatic cancer.
Read more
Long noncoding RNAs in genome stability and cancer
16th April 2021
Dr Lovorka Stojic, Group Leader in the Centre for Cancer Cell & Molecular Biology at Barts Cancer Institute, Queen Mary University of London, has recently received a Cancer Research UK Career Establishment Award to investigate the role of long noncoding RNAs in the maintenance of genome stability and in cancer.
Read more
Impact of chemotherapy on immune cells in the TME
10th April 2021
Research from Barts Cancer Institute, Queen Mary University of London, has revealed novel insights into the effects of chemotherapy on the tumour microenvironment (TME). The study found that chemotherapy enhances the anti-tumour actions of immune cells within the TME and their ability to support immune responses against cancer.
Read more
Combining research and public engagement
8th April 2021
Fran Balkwill, Professor of Cancer Biology at Barts Cancer Institute, Queen Mary University of London, recently wrote a World View article for the journal Nature Reviews Cancer, discussing her dual career in public engagement and research.
Read more
Researchers use machine learning to rank cancer drugs in order of efficacy
25th March 2021
Researchers from Barts Cancer Institute, Queen Mary University of London, have developed a machine learning algorithm that ranks drugs based on their efficacy in reducing cancer cell growth. The approach may have the potential to advance personalised therapies in the future by allowing oncologists to select the best drugs to treat individual cancer patients.
Read more
Ovarian Cancer Perspectives: Q&A with Dr Michelle Lockley
18th March 2021
In recognition of Ovarian Cancer Awareness Month, we spoke with Dr Michelle Lockley, Group Leader and clinical researcher in BCI’s Centre for Cancer Cell and Molecular Biology. Dr Lockley’s research group focuses on improving treatments for women with ovarian cancer, particularly for those whose tumours are resistant to chemotherapy.
Read more